The Synthetic Human Genome (SynHG) Project, launched on the 25th anniversary of the mapping of the human genome, is being ...

The NNF – a philanthropic non-profit organisation that owns a controlling stake in Danish drugmaker Novo Nordisk – has been ...

Success in this area means ensuring the right therapy reaches the patient in a form that is stable, effective, and ready for ...

The European Commission has cleared the high-strength formulation of Eylea (aflibercept) with an extended treatment interval ...

To close the innovation-access gap, there is a desperate need for an infrastructure rooted in trust. That means complementing ...

The CDC's newly constituted Advisory Committee on Immunization Practices (ACIP) has voted to recommend the removal of vaccine ...

Antisense-based therapy salanersen (BIIB115/ION306) is a possible follow-up to Biogen's big-selling Spinraza (nusinersen) ...

It is not clear how AS01 might help lower the risk of dementia, but Oxford University said lab studies show that the adjuvant ...

The Obesity Drug Development Summit Europe is your perfect platform to be in a prime position to be at the forefront of this ...

Kymera Therapeutics is celebrating the signing of two partnerships, with Gilead Sciences taking an option on one molecular ...

At Longeveron, Dr. Joshua Hare and his team are working on an Alzheimer’s treatment using human-derived bone marrow ...

The pharma group has presented phase 1/2 results with new candidate NXT007 at the International Society on Thrombosis and ...